PTC Fully Enrolls Duchenne MD Trial; Expects Top-Line Data In Early 2010
This article was originally published in The Pink Sheet Daily
Executive Summary
With FDA approval of the six-minute walk test as primary endpoint, private specialty firm hopes to bring first Duchenne muscular dystrophy drug to market within two years.